This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Celestica Forms Advisory Council For Growing Healthcare Segment

Stocks in this article: CLS

TORONTO, Nov. 29, 2012 /PRNewswire/ - Celestica Inc. (NYSE, TSX: CLS), a global leader in the delivery of end-to-end product lifecycle solutions, today announced the company's growing healthcare segment "Celestica HealthTech" has formed an Advisory Council to provide critical guidance as the company continues to focus on helping healthcare OEMs accelerate their success.

Celestica's appointed Advisory Council members each possess deep experience and expertise in healthcare technology innovation, product lifecycle and supply chain management, market globalization, regulatory trends and healthcare reform.  The following executives have been appointed to the Advisory Council:

Dr. David Goodman, MD, MSE, currently serves on the Board of Directors of NEUROMetrix (Nasdaq: NURO), a neurotechnology company focused on the early detection of diabetic peripheral neuropathy (DPN) and treatment of painful diabetic neuropathy (PDN).  He also serves as a director of Sound Surgical Technologies LLC, a private manufacturer of aesthetic surgical tools.  Trained in both biomedical engineering and medicine, Dr. Goodman began his career as the first engineer at Nellcor, the company that developed modern pulse oximetry.  Dr. Goodman holds a B.A.S. in applied science and bioengineering and a M.S.E. in bioengineering from the University of Pennsylvania.  He received an M.D. cum laude from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology.  He holds 18 US patents and is licensed to practice medicine in California.

Dr. Eric Maurincomme, PhD, is currently Chief Executive Officer, INSA Lyon, France, one of the top international engineering universities in Europe and Chairman of the Board at Insavalor, its research and technology transfer subsidiary.  He is the former Chief Strategy and Marketing Officer at Agfa Healthcare in Belgium. Previously, Dr. Maurincomme spent 10 years at GE Healthcare as a senior business leader of neurovascular and cardiac imaging product lines.  He is an expert in the area of Imaging and eHealth and served over many years as the Healthcare IT Committee Chairman for the European industry organization COCIR, and as Governing Council Member of HIMSS Europe.

Christopher Van Ingen is Chairman of the Board of Bruker Energy & Superconducting Technologies Inc.; Director of the Bruker Corporation; Chairman of the Board at Accelrys, Inc; Director of Senova Systems, Inc.; and Director of Promega Corporation.  Mr. Van Ingen specializes in life science and analytical instrumentation.  He was President of Agilent Technologies' Bio-Analytical Measurement Group from 2001 to 2007. Prior to that, he had a long career at Hewlett Packard and was Vice President of Sales and Marketing for their Chemical Analysis Group from 1996 to 2001.

The main function of the Advisory Council is to provide valuable market insight and generate actionable strategic input for Celestica as the company develops new and innovative supply chain solutions, designed specifically for the healthcare industry.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs